Clinical Trial

Phase I/II Study of SCTB39G in Advanced Solid Tumours

Name: Phase I/II Study of SCTB39G in Advanced Solid Tumours — clinical trial record (NCT07077252)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Trial Details

NCT Number	NCT07077252
Lead Sponsor	Sinocelltech Ltd.
Conditions	Advanced Malignant Solid Tumor
Enrollment	30 participants
Start Date	2025-07-28
Primary Completion	2027-09-26 (estimated)
Study Completion	2027-10-17 (estimated)
Updated on ClinicalTrials.gov	2025-07-22